Lumateperone: Difference between revisions
From Pharmacopedia
More actions
| [checked revision] | [pending revision] |
MDElliottMD (talk | contribs) Pharmacopedia: remove contraindications parameter |
Sentence-case category link per house style (Mood_Stabilizers → Mood_stabilizers) |
||
| (6 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
{{MedTemplate | {{MedTemplate | ||
| brand = Caplyta | |||
| brand | | classes = Atypical antipsychotic, 5HT2A/D2 antagonist with proposed differential pre/post-synaptic D2 activity | ||
| mechanism = Very high affinity 5HT2A receptor antagonism (~50-fold higher affinity than for D2). Moderate D2 receptor activity proposed to be differential between presynaptic (partial agonist) and postsynaptic (antagonist), if confirmed, this would explain why lumateperone has antipsychotic efficacy at D2 occupancy lower than other antipsychotics. Moderate SERT inhibition (suggests antidepressant potential). | |||
| classes | | uses = Schizophrenia (FDA-approved Dec 2019). Bipolar depression as monotherapy or adjunct to lithium/valproate (FDA-approved Dec 2021). | ||
| mechanism | | starting_dose = 42 mg PO once daily with food (no titration) | ||
| uses | | preparations = 42 mg capsules | ||
| starting_dose | | fda_max = 42 mg/d | ||
| preparations | | routes = Oral | ||
| fda_max | | onset = Antipsychotic effect over weeks | ||
| routes | | duration = Daily dosing | ||
| onset | | halflife = ~18 hours (terminal) | ||
| duration | | bioavailability = Limited but adequate; take with food | ||
| halflife | | pregnancy = Limited data; National Pregnancy Registry for Atypical Antipsychotics | ||
| bioavailability | | legal = Rx | ||
| pregnancy | | intro = '''Lumateperone''' (brand name Caplyta) is an atypical antipsychotic FDA-approved in 2019 for schizophrenia and in 2021 for bipolar depression. Its receptor profile combines very high 5HT2A antagonist affinity with moderate D2 activity that is hypothesized to be differential between pre- and post-synaptic compartments, proposed mechanism is presynaptic D2 partial agonism (reducing DA release) plus postsynaptic D2 antagonism. If this differential is real, it explains efficacy at lower D2 occupancy and the favorable metabolic/motor side effect profile observed clinically. Stahl emphasizes this mechanism story; primary evidence is still preliminary. | ||
| legal | |||
| intro | Lumateperone also has moderate SERT inhibition (mood-relevant), explaining its bipolar depression efficacy. Among atypicals, it has notably low rates of weight gain, metabolic syndrome, prolactin elevation, akathisia, and parkinsonism in trials. | ||
| pharmacodynamics= 5HT2A antagonism Ki ~0.5 nM; D2 antagonism Ki ~32 nM; D1 antagonism Ki ~52 nM; α1A antagonism Ki ~73 nM; SERT inhibition Ki ~33 nM. Minimal H1, M, α2 binding (explains low sedation, no anticholinergic burden, no weight gain). | |||
| pharmacodynamics | | effects = Most common: somnolence/sedation, dry mouth, fatigue, nausea. Low rates of: metabolic effects, weight gain, prolactin elevation, akathisia, parkinsonism, tardive dyskinesia. Class warning: increased mortality in elderly dementia-related psychosis. | ||
| | | interactions = <pharmaInteractions/> | ||
| interactions | |||
}} | }} | ||
[[Category:Second-generation neuroleptics]] | |||
[[Category:Neuroleptics]] | [[Category:Neuroleptics]] | ||
[[Category:Atypical Antipsychotics]] | |||
[[Category:5HT2A Antagonists]] | |||
[[Category:Psychotic Disorders]] | |||
[[Category:Mood stabilizers]] | |||